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Abstract 
Cryopreserved human hepatocytes suspended in human plasma (HHSHP) represent an integrated 
metabolic environment for predicting drug-drug interactions (DDIs).  In this study, 13 CYP3A 
reversible and/or time dependent inhibitors (TDI) were incubated with HHSHP for 20 min over a 
range of concentrations after which midazolam 1’-hydroxylation was used to measure CYP3A 
activity. This single incubation time method yielded IC50 values for the 13 inhibitors. For each 
CYP3A inhibitor/victim drug pair, the IC50 value was combined with total average plasma 
concentration of the inhibitor in humans, fraction of the victim drug cleared by CYP3A and 
intestinal availability of the victim drug to predict the ratio of plasma area under the curve of the 
victim drug in the presence and absence of inhibitor. Of 52 clinical DDI studies utilizing these 13 
inhibitors identified in the literature, 85% were predicted by this method within 2-fold of the 
observed change and all were predicted within 3-fold. Subsequent studies to determine 
mechanism (reversible and TDI) were performed by using a range of incubation periods and 
inhibitor concentrations.  This system differentiated between reversible inhibitors, TDIs and the 
combination of both. When the reversible and inactivation parameters were incorporated into 
predictive models, 65% of 52 clinical DDIs were predicted within 2-fold of the observed changes 
and 88% were within 3-fold. Thus HHSHP produced accurate DDI predictions with a simple IC50 
determined at a single incubation time regardless of the inhibition mechanism, further if needed, 
the mechanism(s) of inhibition can be identified. 
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Introduction 
The inhibition of cytochrome P4503A (CYP3A) enzymes at the intestine and liver is 
responsible for many clinically important drug-drug interactions (DDIs) (Gomez et al., 1995; 
Gorski et al., 1998; Galetin et al., 2008).  It is now a standard practice during drug development 
to predict the ability of candidate drugs to inhibit the cytochrome P450s, including CYP3As, 
using in vitro enzyme kinetic data generated from human liver microsomes (HLMs) (Bjornsson et 
al., 2003a; Bjornsson et al., 2003b). These in vitro CYP inhibition parameters have facilitated the 
assessment of risk and predicted the potential magnitude of DDI when combined with measures 
or predictions of human drug exposure but the approach is time consuming and has significant 
limitations. The state-of-the art prediction of an in vivo CYP-mediated, inhibitory DDI requires 
estimation of the reversible inhibition constant (Ki), the irreversible inhibition parameters (KI and 
kinact), the fraction unbound in plasma (fu,p) and the fraction unbound in the microsomal system 
(fu,mic) (Wang et al., 2004).  Sophisticated models using static or dynamic drug concentration have 
been developed to integrate this data set and predict an in vivo DDI for a given drug dosing 
regimen (Obach et al., 2006; Einolf, 2007; Fahmi et al., 2009; Xu et al., 2009; Rowland Yeo et 
al., 2010).  However, the resulting predictions often result in false positives, false negatives and 
fail to correctly categorize inhibitors as weak, moderate and strong in vivo inhibitors (Xu et al., 
2009). Consequently, a consensus on the most appropriate predictive framework to be used 
during the development of a new drug candidate has not been reached.  
Cryopreserved human hepatocytes suspended in well defined serum free media have been 
used to estimate TDI parameters for diltiazem, verapamil, erythromycin, clarithromycin, and 
troleandomycin, and combined with the Simcyp population-based ADME simulator to accurately 
predict CYP3A mediated DDIs (Xu et al., 2009). The value of this approach in predicting 
reversible inhibition was not assessed by these authors. Cryopreserved human hepatocytes 
suspended in human plasma (HHSHP) represent a convenient, integrated metabolic environment 
for estimating the extent and mechanism of human DDIs. Lu et al. (Lu et al., 2007; Lu et al., 
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2008a; Lu et al., 2008b)  have utilized the HHSHP system to quantitatively determine the 
inhibition of various P450s by ketoconazole and fluconazole. Using this information, CYP-
mediated changes in the area under the curve (AUC) of several victim drugs were predicted 
accurately for DDIs involving these two prototypical competitive inhibitors, but the applicability 
to mechanism based inhibitors (MBI) was not addressed. Compared to in vitro systems using 
HLM, human hepatocytes suspended in human plasma inherently account for several parameters: 
1) the plasma protein and microsomal binding of drug, 2) compound availability to the enzyme in 
its native environment within the cell and 3) metabolism of the compound by both CYP and 
non-CYP pathways including the potential for the formation of inhibitory metabolites.  
The primary objective of the current study using HHSHP is to quantify the ability of a 
simple, single incubation time method to assess the CYP3A inhibition by a test compound in 
order to predict clinical DDIs without the knowledge of  inhibition mechanism.  A secondary aim 
is to identify the inhibition mechanism and compare the clinical DDI prediction based on the 
appropriate mechanistic models to those from the single incubation time method. 
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Materials and Methods 
 
Materials. Cryopreserved human hepatocytes and InVitro GROTM HT Medium were obtained 
from Celsis In Vitro Technologies, Inc. (Baltimore, MD). Midazolam, 1’-hydroxymidazolam (1’ 
OH midazolam) and [13C5]-1’-hydroxymidazolam were obtained from BD Gentest (Woburn, 
MA). Conivaptan was obtained internally. Clarithromycin, diltiazem, erythromycin, fluconazole, 
itraconazole, ketoconazole, nefazodone, and troleandomycin were obtained from Sigma (St. 
Louis, MO). Aprepitant, ritonavir, saquinavir, and voriconazole were obtained from Toronto 
Research Chemicals (North York, ON, Canada).  Human plasma (Na-heparin) was obtained from 
Lampire Biological Laboratories, Inc. (Pipersville, PA). Hepatocyte Maintenance Medium 
(HMM) was obtained from Lonza, Inc. (Walkersville, MD).  
Hepatocyte studies.   Hepatocytes (pool of five individuals) were thawed in InVitro GROTM HT 
Medium (25 ml per 5 million hepatocytes) and centrifuged at 50g at room temperature for 5 min.  
The cell pellet was reconstituted in HMM, and cell viability was found to be at least 80% using a 
Vi-Cell XR cell viability analyzer (Beckman Coulter Inc., Brea, CA).  After the cell viability was 
determined, hepatocytes were centrifuged at 50g at room temperature for 5 min and resuspended 
in human plasma (2x106 cells/ml). The cell suspension was incubated at 37 °C with 5% CO2 until 
the addition of putative enzyme inhibitors. 
Inhibition studies. The final inhibitor concentrations in human plasma were 0.13-100 µM for 
aprepitant, fluconazole, voriconazole, clarithromycin, conivaptan, diltiazem, erythromycin, 
itraconazole, nefazodone and troleandomycin, 0.03-20 µM for ketoconazole and ritonavir, and 
0.07 to 50 µM for saquinavir. The final organic vehicle concentration was 0.5% methanol. The 
incubations were performed in triplicate.  Stock hepatocyte suspension (25 µl) was added to 50 µl 
of inhibitor-containing plasma such that the final concentration of hepatocytes was 0.5×106 
cells/ml in human plasma and incubated for 20 min. (37 °C, 5% CO2) before the addition of 
midazolam. To assess the effect of incubation time, cells were incubated with inhibitors for 0, 10, 
and 20 min. prior to the addition of midazolam. Midazolam (25 µl in human plasma; final 
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concentration = 30 µM) was added to the cell suspension, and a further 35 min of incubation was 
used to quantify the remaining CYP3A activity. The reactions were terminated by adding 200 µl 
of acetonitrile/methanol (3:1 v/v) containing 150 nM [13C5] -1’-OH midazolam as an internal 
standard.  Samples were centrifuged at 4000 rpm for 20 min and an aliquot of the supernatant was 
analyzed by LC-MS/MS. Preliminary experiments demonstrated that these incubation conditions 
resulted in linear formation of 1’-hydroxymidazolam with respect to the incubation time and the 
hepatocyte concentration. The formation of 1’-hydroxymidazolam was linear for 80 minutes. 
Liquid chromatography/tandem mass spectrometry methods. Quantification of 1’-OH midazolam 
was achieved using HPLC (Shimadzu LC10) interfaced to a triple quadrapole mass spectrometer 
(Sciex API 4000, Applied Biosystems, Foster City, CA). Chromatographic separation was 
achieved using a reverse phase column (Synergi Hydro-RP 4 µm column, 100 × 2 mm, 
Phenomenex, Torrance, CA) with a gradient consisting of 5% methanol in 5 mM ammonium 
acetate (mobile phase A) and 95% methanol in 5 mM ammonium acetate (mobile phase B) at a 
flow rate of 0.4 mL/min with a 25 µl injection volume. Specifically, 70% of mobile phase B was 
increased linearly to 80% from 0 to 2 min, and increased to 100% in the next 0.05 min. Mobile 
phase B was held at 100% from 2.05 to 2.30 min, and the column was re-equilibrated to 70% B. 
The electrospray ionization probe was run in the positive ion mode with probe temperature of 600 
°C.  The m/z transition of 1’-OH midazolam and [13C5]-1’-OH midazolam were 342 →324 and 
347 →329, respectively. The lower and upper limits of quantification were 0.5 and 234 pmol 1’-
OH midazolam, respectively, per 100 µL well incubation. The interday accuracy ranged from -
4.97% to 10.26%, and the intraday accuracy ranged from -6.13% to 11.09%. The interday 
precision ranged from 2.47% to 8.15%, and the intraday precision ranged from 1.70% to 13.15%. 
Data analysis. 
Inhibition data.  The relationship between CYP3A activity at a given time and inhibitor 
concentration relative to baseline CYP3A activity was used to determine an IC50.  All data were 
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analyzed using the average of triplicate determinations. IC50 values were calculated by the model 
(Eq. 1) by weighted nonlinear regression (WinNonlin 5.0, Pharsight Corp, Mountain View, CA).   
                                                                                                                                 (Eq. 1)
 
 
Where X is the nominal concentration of an inhibitor; Y represents the percentage of baseline 
CYP3A activity remaining; a is the estimated response at zero concentration of inhibitor; γ is the 
slope factor, describes the steepness of the curve.   
Three inhibition models incorporating irreversible (Model B), reversible (Model C), or 
both (Model A), were employed to estimate the inactivation parameters (KI and kinact) and/or 
reversible inhibition constant (Ki) for each inhibitor when three IC50 curves obtained from 
different incubation times were simultaneously fitted using weighted nonlinear regression. The 
most appropriate model was chosen using the following goodness of fit criteria: visual inspection, 
randomness of the residuals, and the standard error of the parameter estimates. 
 
Model A:                                                                                                                 (Eq. 2) 
 
Model B:                                                                                                                 (Eq. 3) 
 
Model C:                                                                                                                 (Eq. 4) 
 
In Eq. 2-4, t is the time during which the inhibitors are in contact with human hepatocytes 
prior to the addition of midazolam (0, 10 or 20 min). V35+t, [I] represents the formation rate of 1’-
OH midazolam at a given concentration of the inhibitor and total time (total time = 35 min with 
midazolam plus t min without midazolam), and V35+t, [0] is the formation rate of 1’-OH midazolam 
for the corresponding vehicle control (no inhibitor) at the same incubation time. The ratio of V35+t, 
[I] and V35+t, [0] normalizes the baseline for the enzyme activity for the specific incubation time.  Km 
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is the Michaelis-Menten constant for 1’-OH midazolam formation in HHSHP (45 µM, based on 
total and not unbound midazolam concentration, data not shown), and [S] is midazolam 
concentration (30 µM). Vmax, 35 +t   represents maximum rate of 1’-OH midazolam formation at 
some total time.  The rate of 1’-OH midazolam formation varied with incubation time and 
consequently the ratio of Vmax, 35 +t   and V35+t, [0] was estimated by Models A-C (Eq. 2-4).  [I] is the 
nominal inhibitor concentration, assuming no inhibitor depletion during the incubation. KI is the 
inhibitor concentration required for the half maximal inactivation, kinact is the maximum 
inactivation rate constant, and Ki is the reversible inhibition equilibrium constant.  
All raw data were fitted to Model A. If the parameters Ki , kinact and KI with less CV% 
were estimated by Model A from the simultaneous fitting three sets of data corresponding to the 
ratio of 1’-OH midazolam formation rate versus inhibitor concentrations using weighted 
nonlinear regression, it suggested that the compound is a reversible and time dependent inhibitor. 
For compounds which Model A was able to estimate the inactivation parameters (KI and kinact) but 
not the reversible inhibition constant Ki, the raw data were fitted to Model B which only estimates 
the inactivation parameters (KI and kinact). For compounds which Model A was able to estimate 
the reversible inhibition constant Ki but not the inactivation parameters (KI and kinact), the raw data 
were fitted to Model C which only estimates the reversible inhibition constant Ki. 
Predictions of drug-drug interactions.   
The single incubation time method A generic model (Eq. 5) of enzyme inhibition was used to 
predict a potential increase in exposure to a drug as a result of the inhibition of hepatic and 
intestinal CYP3A (Ito et al., 1998; Wang et al., 2004; Obach et al., 2006). All assays were 
performed at a substrate concentration close to the Km of midazolam (data not shown). The 
inhibition mechanism may be unknown for some inhibitors nevertheless the assumption that Ki, 
app= IC50/2 was applied (Obach et al., 2007).  For competitive inhibitors, the Ki, app would be 
equivalent to the inhibition constant Ki.  In the case of TDIs that display mechanism based 
inhibition, Ki, app would be equivalent to KI × kdeg /kinact when [I] << KI  (Wang et al., 2004).  
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
                                                                                                                        DMD # 36400 
10 
 
 
 
                                                                                                                                                 (Eq. 5) 
 
Where AUC p.o.,i/AUC p.o is the predicted ratio of in vivo exposure of a CYP3A-cleared drug with 
oral coadministration of the inhibitor versus that in control state, fm, CYP3A is the fraction of total 
clearance of the affected drug to which CYP3A contributes, Fg is the fraction of the dose of the 
affected drug that passes through the intestine unchanged after p.o. administration in the control 
state.  
The fraction of object drug metabolized by CYP3A (fm,CYP3A) was assumed to be the same 
as that observed previously for midazolam, sildenafil, fentanyl, triazolam, zolpidem, alprazolam 
and trazadone (0.93, 0.79, 0.5, 0.8, 0.6, 0.8, and 0.35, respectively) (Obach et al., 2006). The 
fraction of drug metabolized by CYP3A in the intestine was assumed to be 1, and the Fg values 
for midazolam, sildenafil, triazolam, alprazolam and trazadone were assumed to be 0.57, 0.38, 
0.44, 0.88 and 0.75 respectively, as described previously (Ernest et al., 2005; Obach et al., 2006).  
[I] is collected from three main sources (details in the Supplemental Table 1). The average 
systemic plasma concentration of the inhibitor (plasma concentration area under curve from 0 to 
the dosing interval (AUC0-τ) divided by the dosing interval) observed or calculated in the primary 
literature was preferred. In some cases this was not available and then the plasma inhibitor 
concentration at a certain time point (eg. when the victim drug was administered) reported in the 
primary literature was employed. If the inhibitor concentration was not reported in the primary 
literature, values were obtained from secondary literature sources (Einolf, 2007; Fahmi et al., 
2008; Fahmi et al., 2009). These values were previously derived from other literature in which 
similar dosing regimens were employed for individual inhibitors. The IC50 values are based on 
total inhibitor concentration in plasma and consequently there is no need to use unbound 
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plasma concentrations in the predictions. For the prediction of intestinal inhibition, Ki,app 
values were converted to unbound values (Ki,app  × fu) consistent with the assumption of no 
significant protein binding in the gut lumen. The fraction unbound in human plasma for each 
compound was taken from Goodman & Gilman (Hardman et al., 2001).  
The concentration of the inhibitor in the enterocyte during absorption ([I]g) was estimated 
based on the assumption that 1) no significant protein binding in the gut lumen and 2) 
inhibitors not subject to any first pass metabolism (Rostami-Hodjegan A, 2004; Galetin et al., 
2008): 
                                                 
MWQ
Fk
×
××
=
ent 
aa
g
D[I]                                            (Eq. 6)                                
In which D is the dose of the inhibitor (mg), ka is the oral absorption rate constant of the inhibitor, 
Fa is the fraction of the inhibitor absorbed into the gut wall from the intestinal lumen following 
oral administration, Qent represents the blood flow to the enterocyte, and MW is the molecular 
weight.  For ka and Qent values of 0.03 min-1 and 248 ml/min were used, respectively  (Obach et 
al., 2006). An Fa value of 1 was used for all drugs (Einolf, 2007). 
In the current investigation, there were 12 clinical studies in which victim drugs were 
given intravenously. Among these 12 studies, midazolam was the victim drug in eleven clinical 
studies and the inhibitors were ketoconazole, aprepitant, conivaptan, voriconazole, 
troleandomycin, erythromycin, clarithromycin, diltiazem and saquinavir. In the other clinical 
study, fentanyl was the victim drug and ritonavir was the inhibitor.  For these 12 studies, the AUC 
ratio was predicted using Eq. 7, in which the hepatic extraction ratio (EH) of the victim drug is 
accounted for in the DDI prediction (Kirby and Unadkat, 2010). Midazolam was assignedan EH 
of 0.4 (mean value calculated from the eleven clinical studies) and fenatanyl was assigned a value 
of 0.7 (Olkkola et al., 1999). 
                                                                                                                           (Eq. 7) 
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The mechanistic method According to the inhibition mechanism, the magnitude of DDIs 
involving each inhibitor was predicted using the appropriate models. 
For drugs identified as reversible inhibitors, AUC ratios were calculated by Eq. 5, where 
Ki,app was equal to the Ki estimated by Model C.  
For drugs identified as TDIs with Model B, AUC ratios were calculated using the 
following equation (Mayhew et al., 2000; Wang et al., 2004).  
 
  
 
 
                                                                                                                              ( Eq. 8) 
where kdeg is the first-order rate constant of in vivo degradation of the affected enzyme. The 
values of  kdeg used for intestinal (kdeg,CYP3A,g ) and hepatic CYP3A (kdeg,CYP3A,h ) were 0.000481 ( 
t1/2 = 24 h ) and 0.000321 min -1 ( t1/2 = 36 h ), respectively (Wang et al., 2004; Obach et al., 2007; 
Quinney et al., 2010; Wang, 2010).  For the 12 clinical studies involving IV administration of the 
victim drug, the AUC ratio was predicted using Eq. 9 (Kirby and Unadkat, 2010). 
 
                                                                                                                                                 (Eq. 9) 
 
 
 
For drugs identified as reversible and time dependent inhibitors with Model A, the AUC ratio was 
calculated using Eq. 9 (Fahmi et al., 2008). For the ritonavir and IV fentanyl DDI, the AUC ratio 
was predicted using Eq. 11 (Kirby and Unadkat, 2010). 
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                                                                                                                             ( Eq. 10) 
 
                                                                                                                                  (Eq. 11) 
 
 
Data source.  Data from fifty two clinical DDI studies were collected from the literature after 
having been identified by the University of Washington Metabolism and Transport Drug 
Interaction Database (http://www.druginterationinfo.org/). Forty six clinical DDI studies involved 
the inhibition of midazolam metabolism, 5 studies involved the inhibition of alprazolam, fentanyl, 
sildenafil, trazadone and triazolam metabolism by ritonavir; 1 study involved the inhibition of 
sildenafil by saquinavir. The database was accessed on 01/29/2009, and the data are reported in 
Table 3. 
Data analysis. Among 52 clinical DDIs, there are 22 strong interactions (AUC ratio > 5), 26 
moderate interactions (2 ≤ AUC ratio ≤ 5) and 4 weak interactions (1 ≤AUC ratio < 2). Two 
methods were employed to quantify the accuracy of predicted DDIs. One is to compare the fold 
error of predicted and observed values of AUC ratio (2-fold cut-off). Another method is called 
“categorical prediction” based on the definition of strong interactions, moderate interactions and 
weak interactions. 
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Results 
Enzyme inhibition parameter estimation 
The thirteen known CYP3A inhibitors represented reversible inhibitors (ketoconazole as 
strong reversible inhibitor and fluconazole as a moderate inhibitor) and TDIs (TAO as a strong 
TDI, diltiazem as a moderate TDI, and erythromycin as a weak TDI) that displayed a wide range 
of plasma protein binding (itraconazole and ketoconazole high protein binding, voriconazole and 
clarithromycin moderate protein binding, and fluconazole low protein binding).  These inhibitors 
were incubated with human hepatocytes suspended in human plasma for 20 min over a range of 
concentrations in the absence of midazolam and a further 35 min in the presence of midazolam 
(30 µM). The IC50 value for each inhibitor was estimated using Eq. 1 and the values are shown in 
Table 1. For ketoconazole and fluconazole, the IC50 values obtained here were similiar to those 
observed by Lu et al. using a comparable procedure (Lu et al., 2007; Lu et al., 2008a; Lu et al., 
2008b).  Based on the assumption that the nominal concentration of inhibitor is close to the 
extracellular concentration, these IC50 values represent the total (bound and unbound) 
concentration of the inhibitors that inhibit 50% of CYP3A activity and consequently there was no 
correction of fraction unbound in plasma for the IC50 values. As shown in Table 1, ritonavir was 
the most potent inhibitor with the lowest IC50 value, while aprepitant had the highest IC50 value 
among the 13 drugs studied.  In additional studies, incubation times of 0, 10 and 20 min (with 
inhibitors alone) were used to generate IC50 values (Table 1). The IC50 value at the 20 min in the 
two independent studies showed very good agreement (Table 1). 
To define the inhibition mechanism for each inhibitor, models of reversible inhibition 
(Model C), irreversible inhibition (Model B), and combined reversible and irreversible inhibition 
(Models A) were employed (Eq. 3-5). Examples of the results of the best fit of four representative 
drugs (ketoconazole, erythromycin, itraconazole and ritonavir) are shown in Fig. 1a-d, and the in 
vitro inhibition constants for each inhibitor obtained from the best model fit analyses are listed in 
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Table 2. The process of defining the inhibition mechanism took place in the following three steps. 
First, all raw data were fitted to the combined reversible plus irreversible model (Model A). The 
fit of Model A indicated that ketoconazole is a reversible inhibitor but not a TDI because Model 
A was able to estimate the reversible inhibition constant Ki but not the inactivation parameters (KI 
and kinact). This observation was also the case with fluconazole, aprepitant and voriconazole, 
which is not unexpected because these compounds are all known reversible inhibitors (Ito et al., 
1998). A second group of compounds (erythromycin, nefazodone, troleandomycin, 
clarithromycin, diltiazem, itraconazole and saquinavir) were identified as TDI only, because 
Model A was able to estimate the inactivation parameters (KI and kinact) for each with reasonable 
precision but not the reversible inhibition constant Ki. Ritonavir represents a potential third group 
of compounds as it was suggested to be a reversible and time-dependent inhibitor because both 
the reversible inhibition constant Ki and the inactivation parameters (KI and kinact) were well 
estimated (Fig. 1d and Table 2).  
In the second step of assigning a mechanism, inhibitors which were initially assigned as 
TDIs only were further analyzed using the model for irreversible inhibition (Model B), which 
only estimates the inactivation parameters (KI and kinact). Better fitting of the data and more 
precise (less CV%) estimates of inactivation parameters of these inhibitors (TDI only) were 
obtained utilizing Model B (Fig. 1b-c and Table 2). For example, the fit of erythromycin to 
model A resulted in the mean estimate and the standard error of the estimates of kinact, KI  and Ki  
as 0.08 ± 0.07 min-1 (87.50 % CV), 35.09 ± 31.92 μM (90.97 % CV) and 497.65 ± 8311.13 μM 
(1670.09 % CV),  where as the results were significantly better when the data were fit to 
model B yielding the values of kinact and KI  as  0.08 ± 0.005 min-1 (6.25 % CV) and 25.15 ± 
4.90 μM (19.48 % CV), respectively. In the third step, inhibitors which were identified as purely 
reversible inhibitors in the first step were analyzed using Model C, which only estimates the 
reversible inhibition constant Ki. Better fitting of the data and more precise (less CV%) estimates 
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of Ki for these inhibitors were obtained utilizing Model C (Fig. 1a and Table 2). For example, 
the fit of ketoconazole to model A resulted in the mean estimate and the standard error of the 
estimates of kinact, KI and Ki  as 0.000003 ± 0.2 min-1 (7686821 % CV), 32.67 ± 8543863 μM 
(10845820 % CV) and 0.61 ± 0.18 μM (29.51 % CV),  where as the results were significantly 
better when the data were fit to model C yielding the value of Ki as  0.59 ± 0.09 μM (15.25 
% CV). In addition, Model C also fitted the ritonavir data well, which was not surprising as the 
compound was reported as a very potent reversible as well as a TDI in HLM (Ernest et al., 2005). 
Thus, the inhibition constants of ritonavir estimated from both models have been included in 
Table 2.   
Prediction of DDIs 
The in vitro inhibition constants for the thirteen CYP3A inhibitors studied were used to 
predict 52 clinical DDIs (Table 3) using the single incubation time method and mechanistic 
method. In these studies, for 12 of the 13 inhibitors the victim drug was midazolam; for ritonavir 
the victim drugs were sildenafil, fentanyl (intravenous), triazolam, alprazolam and trazodone; for 
saquinavir one of the victim drugs was sildenafil.  
The single incubation time method: IC50 values from a 20 min incubation with inhibitor alone  
IC50 values from a 20 min incubation time with inhibitor and a further 35 min of 
incubation with midazolam were converted to Ki,app (Ki,app=IC50 / 2) and used in Eq. 5 to predict 
the extent of DDI in vivo. The total average systemic plasma concentration of each inhibitor was 
employed as [I] because in vitro parameters were estimated relative to total plasma 
concentration there was no need for correction for the fraction unbound in plasma for [I] 
(Table 3); [I]g was calculated using Eq.6. The predicted and observed AUC ratios are listed in 
Table 3, and a plot of predicted DDIs versus observed values from clinical studies is shown in Fig 
2. The single incubation time method correctly classified DDIs in 12 out of 20 strong interactions 
(60% accuracy), 15 out of 28 moderate interactions (54% accuracy) and 4 out of 4 weak 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
                                                                                                                        DMD # 36400 
17 
 
interactions (100% accuracy) (Fig. 2). Using the criteria of within 2-fold of the observed value for 
an accurately predicted DDI, this approach correctly predicted 44 out of 52 clinical DDIs (85% 
accuracy) (Fig. 2). The predictions for the remaining outliners (8 out of 52) were within-3 fold of 
the observed values and included 2 cases for fluconazole, 2 case for voriconazole, 2 cases for 
saquinavir, and 2 cases for clarithromycin. There were no false positive or false negative 
predictions. 
The mechanistic method: utilizing in vitro parameters estimated by Models A-C 
As described in Materials and Methods, each DDI was also predicted according to the 
inhibition mechanism of the compound. The magnitude of DDIs for the four reversible inhibitors 
(ketoconazole, aprepitant, fluconazole and voriconazole identified by Model C) was predicted by 
Eqs. 5 and 7. DDIs with the 8 TDI inhibitors (troleandomycin, saquinavir, clarithromycin, 
conivaptan, diltiazem, erythromycin, itraconazole and nefazodone identified by Model B) were 
predicted by Eqs. 8 and 9. DDIs with ritonavir, which was identified as a reversible and time 
dependent inhibitor by Model A, were predicted by Eqs. 10 and 11. Total average systemic 
plasma concentration of each inhibitor was used as [I] because in vitro parameters were 
estimated relative to total plasma concentration (Table 3); [I]g was calculated using Eq.6.  
Predicted AUC ratios are listed in Table 3, and plots of predicted DDIs versus observed values 
from clinical studies are shown in Fig 3. This approach correctly classified DDIs in 18 out of 20 
strong interactions (90% accuracy), 4 out of 28 moderate interactions (14% accuracy) and 3 out 
of 4 weak interactions (75% accuracy), respectively (Fig. 3). This approach predicted 34 out of 52 
clinical DDIs (65% accuracy) within 2-fold of the observed AUC changes and 46 out of 52 
clinical DDIs (88% accuracy) within 3-fold (Fig. 3). Predictions that were more than 3-fold 
different from observed values involved 1 case for saquinavir, 1 cases for erythromycin, 1 case 
for clarithromycin, 1 case for diltiazem and 2 cases for conivaptan. There were no false positive 
or false negative predictions. 
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Predictive performance of the single incubation time method for each of the three inhibition 
mechanisms  
Eight inhibitors were identified as TDIs by Model B, and the single incubation time 
method correctly classified the DDI caused by these 8 TDIs in 4 out of 10 strong interactions 
(40% accuracy); 9 out of 19 moderate interactions (47% accuracy) and 1 out of 1 weak 
interactions (100% accuracy). For 4 reversible inhibitors, the single incubation time method 
correctly classified the DDIs in 6 out of 8 strong interactions (75% accuracy); 4 out of 6 moderate 
interactions (67% accuracy) and 3 out of 3 weak interactions (100% accuracy). For ritonavir, the 
single incubation time method correctly classified DDIs in four interactions (75% accuracy). 
When the 2-fold cut-off criteria was used to evaluate the performance of the single incubation 
time method, 25 out of 30 clinical DDIs were predicted correctly for TDIs (83% accuracy), 14 out 
of 17 clinical DDIs were predicted correctly for reversible inhibitors (82% accuracy), and 5 out of 
5 clinical DDIs were predicted correctly for reversible and time dependent inhibitor ritonavir 
(100% accuracy). This retrospective analysis suggested that the single incubation time method 
was a strong predictor of DDIs due to TDIs as well as reversible inhibitors when the 2-fold 
criterion was used.  
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Discussion  
Hepatocytes obtained in well defined serum free media have previously been 
demonstrated to be a useful system for the estimation of CYP3A inhibition parameters (Zhao et 
al., 2005; McGinnity et al., 2006; Brown et al., 2007; Xu et al., 2009).  Zhao et al. (2005) 
evaluated time dependent inactivation of CYP3A in cryopreserved human hepatocytes for six 
drugs (amprenavir, diclofenac, diltiazem, erythromycin, raloxifene and TAO), and the IC50 values 
for hepatocytes were 2- to 60-fold higher than those for HLM after correcting for factors such as 
nonspecific binding and inhibitor consumption in hepatocytes. McGinnity et al. (2006) incubated 
three CYP3A inhibitors (erythromycin, TAO and fluoxetine) with cultured primary human 
hepatocytes for 48 hours, and the parameters associated with irreversible inhibition were in good 
agreement with those generated with HLM although lower values of kinact were observed in both 
Hepatocytes and HLM systems compared to the recombinant CYP3A. Brown et al. (2007) 
investigated six drugs (miconazole, ketoconazole, fluconazole, quinine, fluoxetine and 
fluvoxamine) in both rat micosomes and freshly isolated rat hepatocytes, and indicated that these 
systems gave similar estimates of inhibitory potency after correction for the nonspecific binding 
in each system for these CYP3A inhibitors. However, although all three studies noted above 
(Zhao et al., 2005; McGinnity et al., 2006; Brown et al., 2007) compared the in vitro inhibition 
parameters generated from microsomes to those from hepatocytes, the question of whether the 
parameters generated from hepatocytes resulted in an improved ability to predict human DDIs 
was not addressed.  Xu et al. (2009) noted that the values of kinact in HLM were higher and the 
values of unbound KI in HLM were lower than those estimated in cryopreserved human 
hepatocytes. The in vitro inactivation  parameters from cryopreserved human hepatocytes resulted 
in good overall prediction of in vivo DDI extent but there was a systematic over prediction with 
HLM data (Xu et al., 2009), and both hepatocyte and HLM prediction resulted in several false 
negative predictions. Lu et al. expanded the utility of cryopreserved human hepatocytes by using 
a suspension in human plasma and demonstrated a good agreement between predicted and 
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observed clinical DDIs involving  two known CYP3A inhibitors, ketoconazole and fluconazole 
(Lu et al., 2007; Lu et al., 2008a; Lu et al., 2008b). In the present report, the utility of 
cryopreserved human hepatocytes suspended in human plasma to predict in vivo DDIs was 
further explored using 13 reversible and TDIs of CYP3A and midazolam as the probe substrate.  
The approach to predict CYP3A DDI prediction utilized in the current report did not 
focus on an initial characterization of the mechanism of inhibition but rather employed a single 
IC50 measurement in hepatocytes suspended in human plasma; an analogous approach has been 
described in the HLM system (Obach et al., 2007; Grime et al., 2009; Burt et al., 2010). This 
single incubation time method captures both reversible and TDI by using appropriate 
experimental conditions. In these studies, 0.5x106 cryopreserved hepatocytes per ml were used 
because this is similar to 0.17 mg/ml HLM protein, a concentration commonly used in studies in 
HLMs (based on the scaling factors of 120 x 106 hepatocytes cells/g liver and 40 mg HLM/g 
liver). The inhibitor-alone incubation time with hepatocytes was 20 min and this would be 
expected to result in almost complete CYP3A inactivation given a typical HLM kinact value of 
approximately 0.1 min-1. However, it should be noted that the values of kinact of clarithromycin 
and saquinavir were 0.064 and 0.033, respectively (t1/2 respectively of 11.55 min and 20.02 min), 
and these relatively low values likely contributed to the DDI under-prediction for these two 
compounds (Table 3). The concentration of midazolam, employed to determine residual CYP3A 
activity (30 μM), was close to the Km value of 45 μM in HHSHP (preliminary experiments, and 
the estimate is based on total and not unbound midazolam concentration) to capture reversible 
inhibition in the IC50 measurement. The formation of 1’-hydroxymidazolam over a 35 min 
incubation time was used the quantify CYP3A activity. Under these conditions, metabolite 
formation was linear over time and yielded sufficient analytical response to characterize extensive 
CYP3A inhibition.  
  The results presented demonstrate that an IC50 value generated from a single incubation 
time was able to adequately predict the magnitude of an in vivo DDI (Table 3, Fig. 2). This IC50 
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value is combined with the total average systemic plasma concentration of the inhibitor in a 
predictive model that incorporates the fraction of the victim drug cleared by CYP3A, and 
intestinal availability of the victim drug (Eq. 5). This differs from previous approaches wherein 
the mechanism(s) of inhibition needs to be identified prior to the parameter estimation in vitro 
and DDI prediction in vivo. This single incubation time method was able to predict 85 % of 52 
clinical CYP3A DDI studies within 2-fold of the observed change in AUC regardless of the 
inhibition mechanism (Fig. 2). The high rate of successful prediction of DDI suggests that this 
relatively simple, mechanism independent approach will be of great use to determine the potential 
for CYP3A mediated DDIs for new candidates and previously uncharacterized molecules. This 
single incubation time approach to predicting DDIs may be particularly useful for 
molecules with a potential for exhibiting TDI in the early discovery stage when the 
standard time-consuming process of estimating the inactivation parameters (KI and kinact) 
in HLM may not be feasible. Although the single time point method may not provide the 
inhibition mechanism, it was able to accurately predict the DDIs related to 8 TDIs. 
Among these 8 TDIs, itraconazole is believed to exhibit  TDI due to the inhibitory metabolite 
formation (Isoherranen et al., 2004; Kunze et al., 2006; Quinney et al., 2008a; Templeton et al., 
2008) whereas the remaining seven TDIs were known to display MBI. The potential of predicting 
the interaction due to the inhibitory metabolite formation without synthesizing and testing the 
metabolite is an important feature of this model particularly  useful in the discovery phase of the 
development of a new chemical entity, since identification of the exact structure of the metabolite 
often may not be available in early discovery.   
It is well known that the expression of CYP3A enzymes in enterocytes results in 
significant presystemic intestinal metabolism of drugs and possible gut wall DDIs after oral 
administration (Schwenk, 1988; Kaminsky and Fasco, 1991; Paine and Oberlies, 2007). Clinical 
studies included in the dataset used in this investigation showed that ketoconazole, voriconazole, 
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troleandomycin, erythromycin, clarithromycin, diltiazem and conivaptan treatments led to a 
higher AUC increase for oral midazolam than for intravenous midazolam. These observations are 
consistent with significant inhibition of gut wall CYP3A given that midazolam is a drug with  a 
moderate hepatic extraction ratio. The single incubation time method showed accurate prediction 
for both intravenous and oral midazolam AUC changes with erythromycin, clarithromycin, 
diltiazem, TAO and conivaptan. For example, clarithromycin administration (500 mg bid for 7 
days) led to an increase in the AUC of midazolam by 3.20-fold following intravenous dosing and 
8.00-fold following oral dosing (Quinney et al., 2008b). The corresponding predictions using the 
single incubation time method were 2.47-fold and 6.18-fold increases in midazolam AUC, 
respectively. In some cases, the oral midazolam DDI (e.g. ketoconazole) has not been well 
predicted.  The reason for such an outcome is that the value of 0.57 which has been used as Fg for 
midazolam in this investigation (Ernest et al., 2005; Obach et al., 2006) is higher than the true 
value observed in some of clinical DDI studies. For instance, Tsunoda et. al. (1999), estimated the 
Fg value for midazolam to be 0.40 (assuming Fa=1). In order to illustrate the impact of Fg value to 
the DDI prediction outcome, another set of DDI predictions based on Fg, midazolam = 0.40 was 
constructed (Fig. 4a). The clinical studies with victim drugs other than midazolam were excluded 
from this figure. For the eleven clinical studies in which midazolam was dosed intravenously, the 
difference in Fg, midazolam would not influence the outcome of these DDI predictions. When Fg, 
midazolam = 0.40 was used,  it was found that 38 out of 46 clinical DDIs were predicted within 2-
fold of the observed value (83% accuracy), 44 out of 46 within 3-fold of the observed value (95% 
accuracy), and only 2 out of 46 have been slightly overpredicted beyond the 3-fold range. For the 
ketoconazole-midazolam interaction from Tsunoda et. al. (1999), the prediction was improved 
from 8.47 to 12.05 and is closer to the observed value of 16-fold AUC change due to a better 
representation of the intestinal interaction when Fg, midazolam = 0.40. This example reinforces the 
concept that it is not only the in vitro inhibition parameters that influence the quality of the final 
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DDI prediction, but also whether the pharmacokinetic parameters utilized in the model (Fg and fm 
for the victim drug) represent the population in a specific clinical DDI study. 
Although there is no need to correct the systemic plasma concentration [I] with fu,p for the 
hepatic interaction prediction when the Ki,app  values generated from hepatocytes plasma were 
utilized, the fu,p value was used to correct the Ki,app  for the intestinal interaction prediction because 
entocytes are considered as plasma protein-free environment. It is worthwhile to note that the 
intestinal inhibitor concentration calculated from the current model often exceeds the solubility of 
these drugs in intestinal fluid and generally is much higher than the Ki,app before any fu,p correction 
([I]g >>Ki,app). As a result the inhibitors examined in this study are predicted to completely inhibit 
the CYP3A in gut wall over the time during which the victim drugs are absorbed. Therefore, the 
final intestinal DDI prediction depends only on the value of Fg.  This point is illustrated in Figure 
4b, where there is no fu,p correction for the Ki,app in the intestinal interaction and the outcome of  
DDI prediction was similar to the performance when fu,p was employed. One exception to this 
general observation was the case of aprepitant, which displays high a Ki,app value and a fu,p 
correction is needed for the optimal prediction of the intestinal wall DDI component.  
Following initial identification of inhibitors and DDI prediction by single incubation time 
method, it may be desirable when examining new compounds to characterize the inhibition 
mechanism and estimate specific enzyme inhibition parameters. In the mechanistic approach, the 
incubation times with the inhibitor are 0, 10 and 20 min, and three IC50 curves are generated. All 
the data are incorporated into three models A-C (Eqs. 2-4) which are designed to differentiate 
reversible inhibitors, TDIs and inhibitors with both properties.  These models were used to 
correctly indentify ketoconazole, aprepitant, fluconazole and voriconazole as reversible 
inhibitors; erythromycin, troleandomycin, saquinavir, clarithromycin, conivaptan, diltiazem, 
itraconazole and nefazodone as TDIs; ritonavir as a reversible and time dependent inhibitor. The 
in vitro inhibition constants estimated from the mechanistic models A-C were used to predict the 
magnitude of a DDI when combined with the total average plasma concentration of the inhibitor 
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and incorporated into corresponding equations. With the knowledge of inhibition mechanism, 
65% of 52 clinical DDIs were accurately predicted within 2-fold of the observed fold change in 
AUC (Fig. 3).  
The results reported here on the prediction of CYP3A DDIs using inhibitory parameters 
generated with human hepatocytes suspended in human plasma demonstrated that this robust 
system overcomes a number of perceived weaknesses associated with other in vitro approaches. 
In particular this model provides an integrated cellular environment in which all modes of hepatic 
metabolism are retained and the uncertainty in concentration of inhibitor at the enzyme is greatly 
reduced. The single incubation time method simply requires a single inhibition parameter to 
predict the DDI caused by CYP3A inhibition, and there is no need to correct for nonspecific 
binding. Furthermore, in these predictions the total average systemic plasma concentration of the 
inhibitor provides a reasonable value for both reversible inhibitors and TDIs without the need for 
the determination of fraction unbound in plasma to calculate unbound drug concentrations. The 
study design for inhibition using HHSHP has been simplified such that there is only one time 
point, no dilution step (often performed with TDIs in HLM incubation) and the same midazolam 
concentration (close to its Km) is used in all IC50 assessments. This simple protocol design is 
achievable due to the fact that Model A has demonstrated the capability to extrapolate the 
reversible and time dependent inhibition properties simultaneously.  
 In summary, cryopreserved human hepatocytes suspended in human plasma were 
determined to be a robust and reliable system for the prediction of CYP3A DDIs. These 
predictions may be made by utilizing an IC50 determined at a single incubation time regardless of 
the inhibition mechanism, and if needed, mechanism may also be explored with the mechanistic 
method. 
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Figure Legends 
 
Figure 1.  Relationship between the relative CYP3A activity and inhibitor concentration. The 
relative CYP3A activity is determined as the rate of 1’-OH midazolam formation in the 
presence of inhibitor to that in the absence of inhibitor.  The best fit among three models for 
each inhibitor was chosen and presented as following: a.) ketoconazole by Model C; b.) 
erythromycin by Model B; c.) itraconazole by Model B; d.) ritonavir by Model A. The closed 
circles represent 0 min inhibitor incubation alone, and the solid lines represent the best fits for 0 
min inhibitor concentration; the closed diamonds represent 10 min inhibitor incubation alone, and 
the long dashed lines represent the best fits for 10 min inhibitor concentration; the closed squares 
represent 20 min inhibitor incubation alone, and the dotted lines represent the best fits for 20 min 
inhibitor concentration.   
Figure 2. The single incubation time method: comparison of observed versus predicted AUC 
ratios.  The square boxes correspond to areas of weak (1 to 2-fold increase in AUC ratio), 
moderate (2 to 5–fold increase in AUC ratio) and strong (> 5-fold increase in AUC ratio) 
inhibition.  The solid line depicts the line of unity; the long dashed line represents a twofold 
deviation from unity; the short dashed line represents a threefold deviation from unity (13 drugs 
and 52 clinical DDIs).  
Figure 3. The mechanistic method: comparison of observed versus predicted AUC ratios (13 
drugs and 52 clinical DDIs). The square boxes correspond to areas of weak (1 to 2-fold increase 
in AUC ratio), moderate (2 to 5–fold increase in AUC ratio) and strong (> 5-fold increase in 
AUC ratio) inhibition.  The solid line depicts the line of unity; the long dashed line represents a 
twofold deviation from unity; the short dashed line represents a threefold deviation from unity. 
Figure 4. The single incubation time method: comparison of observed versus predicted AUC 
ratios.  Panel a: The square boxes correspond to areas of weak (1 to 2-fold increase in AUC 
ratio), moderate (2 to 5–fold increase in AUC ratio) and strong (> 5-fold increase in AUC ratio) 
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inhibition.  The solid line depicts the line of unity; the long dashed line represents a twofold 
deviation from unity; the short dashed line represents a threefold deviation from unity (12 drugs 
and 46 clinical DDIs). The baseline value of Fg,midazolam used in Fig. 2 (0.57) were changed to 0.40. 
Panel b, fu,p used in Fig 2 were changed to 1  (no fu,p correction of Ki,app for the intestinal 
interaction, 13 drugs and 52 clinical DDIs).  
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Table 1.  IC50 values of inhibitors from human hepatocytes suspended in human plasma: 
single IC50 assessment (20 min inhibitor incubation alone) and independent multiple IC50 
assessment (0, 10 and 20 min inhibitor incubation alone). 
Inhibitor IC50 (µM) 
 
Single IC50 
assessment 
 Multiple IC50 assessment 
Inhibitor incubation alone 
(min) 
20 0 10  20 
Ketoconazole
 
1.26 ± 0.23 0.98 ± 0.14 1.08 ± 0.11 1.14 ± 0.21 
Fluconazole 7.61 ± 2.67 7.05 ± 1.83 8.05 ± 1.78 7.57 ± 2.34 
Aprepitant 24.10 ± 7.30 35.62 ± 8.30 38.10 ± 10.40 23.09 ± 6.80 
Voriconazole 3.01 ± 0.58 3.82 ± 0.73 4.20 ± 0.39 3.32 ± 0.64 
Nefazodone 1.70 ± 0.31 27.21 ± 9.15 4.75 ± 0.93 1.59 ± 0.23 
Troleandomycin 0.16 ± 0.02 3.48 ± 0.49 0.54 ± 0.11 0.23 ± 0.03 
Erythromycin 2.64 ± 0.93 12.73 ± 3.02 4.79 ± 0.89 2.58 ± 0.82 
Clarithromycin
 
1.98 ± 0.60 16.24 ± 4.11 2.55 ± 1.33 1.68 ± 0.47 
Diltiazem 1.94 ± 0.24 3.83 ± 0.88 2.22 ± 0.73 2.28 ± 0.99 
Saquinavir 4.57 ± 0.52  5.56 ± 1.06 7.09 ± 3.26 3.83 ± 0.64 
Itraconazole
 
0.22 ± 0.05 0.78 ± 0.12 1.22 ± 0.15 0.37 ± 0.06 
Conivaptan 1.70 ± 0.56 46.11 ± 15.97 2.69 ± 0.67 1.53 ± 0.17 
Ritonavir 0.15 ± 0.01 0.16 ± 0.01 0.13 ± 0.01 0.13 ± 0.01 
Note: Each number represents the mean and standard error of estimate of triplicates. 
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Table 2. Inhibition constants predicted from the best fit of models A-C. 
Inhibitor 
 
Inhibition constant 
 
Predicted by 
Model* 
Ki (µM) KI (µM) kinact (min-1) 
Ketoconazole
 
C 0.59 ± 0.09 
  
Fluconazole C 4.01 ± 0.62 - - 
Aprepitant C 11.34 ± 0.72 - - 
Voriconazole C 1.62 ± 0.13 - - 
Nefazodone B - 22.43 ± 7.37 0.05 ± 0.005 
Troleandomycin B - 5.93 ± 1.32 0.07 ± 0.003 
Erythromycin B - 25.15 ± 4.90 0.08 ± 0.005 
Clarithromycin B - 37.43 ± 9.24 0.09 ± 0.008 
Diltiazem B - 2.71 ± 0.73 0.04 ± 0.004 
Saquinavir B - 4.67 ± 2.35 0.03 ± 0.005 
Itraconazole B - 5.14 ± 1.37 0.05 ± 0.001 
Conivaptan B - 3.26 ± 1.10 0.03 ± 0.004 
Ritonavir A 8.59 ± 3.75 0.82 ± 0.14 0.09 ± 0.01 
Ritonavir C 0.06 ± 0.01 - - 
* Three inhibition models incorporating irreversible (Model B), reversible (Model C), or both 
(Model A), were employed to estimate the inactivation parameters (KI and kinact) and/or reversible 
inhibition constant (Ki) for each inhibitor. Refer to the Methods Section for details of the models. 
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Inhibitor Inhibitor Dose 
Regimen* 
[I]¶
 
(µM) 
fu,p Victim drugדּ      Predicted    
in AUC  
 
Single 
incubation 
time #   
Fold increase 
 
 
Mechanistic 
method$ 
Observed fold-
increase in 
AUC¥ 
(Mean±SD) 
Reference 
Ketoconazole 400 mg, qd, 4d, p.o. 2.82 0.01 Midazolam 
D4, 1h after 
7.52 7.59 15.90 ± 2.90 (Olkkola et al., 1994) 
Ketoconazole 400 mg, qd, 10d, p.o. 2.82 0.01 Midazolam 
D6 
7.50 7.59 9.51 (Chung et al., 2006) 
Ketoconazole 200 mg, bid, 2d, p.o. 3.46  0.01 Midazolam 
D1, 2nd 
8.47 8.53 16.00 ± 6.1  (Tsunoda et al., 1999) 
Ketoconazole 200 mg, bid, 2d, p.o 3.46  0.01 Midazolam, i.v. 
D1, 2nd 
3.21 3.32 5.10 ± 1.90 (Tsunoda et al., 1999) 
Ketoconazole 200 mg, bid, 2d, p.o. 4.76  0.01 Midazolam 
D2 
10.07 10.16 6.47 ± 3.4 (Eap et al., 2004) 
Ketoconazole 200 mg, qd, 12d, p.o.  1.88  0.01 Midazolam 
D12, 1h after 
5.95 6.00 7.72 ± 5.96 (Lam et al., 2003) 
Ketoconazole 200 mg, sd, p.o. 1.87  0.01 Midazolam 
2h after 
5.93 5.99 6.45 (McCrea et al., 1999) 
Fluconazole 400 mg, sd, p.o. 21.55 0.89 Midazolam 
2h after 
8.25 7.99 3.51 ± 1.7 (Olkkola et al., 1996) 
Fluconazole D1: 400mg; D2-D5: 
200 mg, qd, p.o. 
29.99  0.89 Midazolam 
D6, 2h after 
9.75 9.46 3.60 ± 2.1 (Olkkola et al., 1996) 
Fluconazole 100 mg, sd, p.o. 5.6  0.89 Midazolam 
1h after 
3.71 3.60 2.16 ± 1.2 (Kharasch et al., 2005) 
Table 3.  Predictions of CPY3A mediated DDIs from in vitro inhibition parameters using the single incubation time method and the 
mechanistic method (52 clinical DDIs/13 drugs) 
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Aprepitant 125mg, sd, p.o. 1.72  0.05 Midazolam 
1h after 
1.96 1.86 2.27 (Majumdar et al., 2003) 
Aprepitant D1: 125mg; D2-5: 
80mg, qd, p.o. 
2.22  0.05 Midazolam 
D5, 1h after 
2.02 1.90 3.30 (Majumdar et al., 2003) 
Aprepitant 40mg, sd, p.o. 0.41 0.05 Midazolam 
1h after 
1.72 1.67 1.22 (Majumdar et al., 2003) 
Aprepitant D1: 40mg; D2-5: 
25mg, qd, p.o. 
0.3  0.05 Midazolam 
D5, 1h after 
1.71 1.70 1.02 (Majumdar et al., 2003) 
Aprepitant 125 mg, sd. p.o. 3.11 0.05 Midazolam, i.v 
1h after 
1.14 1.15 1.47 ± 0.14 (Majumdar et al., 2007) 
Voriconazole D1: 400mg; D2: 
200mg, bid, p.o. 
1.64 0.42 Midazolam, i.v. 
D2, 1h after 
1.57 1.53 3.61 (Saari et al., 2006) 
Voriconazole D1: 400mg; D2: 
200mg, bid, p.o. 
1.46 0.42 Midazolam 
D2, 1h after 
3.23 3.16 9.85 (Saari et al., 2006) 
Nefazodone D1-D4: 100mg 
titration to 200mg, 
bid; D5-D12: 200mg, 
bid, p.o. 
1.73 0.01 Midazolam 
D12, 1h after 2nd 
4.66 11.66 4.44 (Lam et al., 2003) 
Troleandomycin 500 mg, bid, p.o.  1.76 0.04 Midazolam, i.v. 
2h after 1st 
5.83 7.20 3.02 ± 1.44 (Phimmasone and Kharasch, 
2001) 
Troleandomycin 500 mg, bid, p.o. 1.76 0.04 Midazolam, i.v. 
2h after 1st 
5.83 7.20 4.50 ± 1.0 (Kharasch et al., 2004) 
Troleandomycin 500 mg, bid, p.o. 1.76 0.04 Midazolam 
2h after 1st 
15.88 19.79 15.70 ± 2.17 (Kharasch et al., 2004) 
Erythromycin 200 mg, qid,7d,  p.o.  0.44 0.16 Midazolam 
D7, 1h after 1st 
2.37 6.87 3.38 ± 1.40 (Okudaira et al., 2007) 
Erythromycin 200 mg, qid, 4d, p.o.  0.44 0.16 Midazolam 
D4, 1h after 1st 
2.37 6.87 3.38 ± 1.60 (Okudaira et al., 2007) 
Erythromycin 200 mg, qid, 2d, p.o.  0.44 0.16 Midazolam 
D2, 1h after 1st 
2.37 6.87 2.32 ± 0.90 (Okudaira et al., 2007) 
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Erythromycin 500 mg, tid, 5d, p.o. 0.95 0.16 Midazolam 
D5, 1.5h after 1st 
3.08 10.46 3.81 ± 0.70 (Zimmermann et al., 1996) 
Erythromycin 500 mg, tid, 6d, p.o. 4.22 0.16 Midazolam 
D6, 2h after 2nd 
6.47 18.05 4.41 ± 1.04 (Olkkola et al., 1993) 
Erythromycin 500 mg, tid, 6d, p.o. 1.64 0.16 Midazolam, i.v. 
D6, 2h after 2nd 
1.64 5.11 2.17± 0.38 (Olkkola et al. 1993) 
Clarithromycin 500 mg, bid, 7d, p.o. 0.90 0.5 Midazolam, i.v. 
D7, 2h after 1st 
1.50 3.51 3.10 ± 0.70 (Gorski et al., 1998) 
Clarithromycin 500 mg, bid, 7d, p.o. 3.20 0.5 Midazolam, i.v. 
D7, 2h after 1st 
2.47 5.84 3.20 ± 0.60 (Quinney et al., 2008b) 
Clarithromycin 250 mg, bid, 5d, p.o. 2.4 0.5 Midazolam 
D5, 1.5h after 1st 
5.24 14.11 3.60 (Yeates et al., 1996) 
Clarithromycin 500mg, bid, 7d, p.o. 0.90 0.5 Midazolam 
D7, 2h after 1st 
3.19 8.89 8.10 ± 2.40 (Gorski et al., 1998) 
Clarithromycin 500mg, bid, 7d, p.o. 3.20 0.5 Midazolam 
D7, 2h after 1st 
6.18 15.64 8.00 ± 2.20 (Quinney et al., 2008b) 
Clarithromycin 500mg, bid, 7d, p.o. 0.90 0.5 Midazolam 
D7, 2h after 1st 
3.19 8.89 5.75 ± 0.62 (Gurley et al., 2008) 
Clarithromycin 500mg, bid, 7d, p.o. 0.90 0.5 Midazolam 
D7, 2h after 1st 
3.19 8.89 7.79 ± 1.79 (Gurley et al., 2006) 
Diltiazem D1: 60mg, bid; D2: 
60mg, tid, p.o. 
0.38 0.22 Midazolam 
D2, 1h after 2nd 
2.36 13.69 3.75 ± 0.11 (Backman et al., 1994) 
Diltiazem 120mg, bid, 6d, p.o. 0.16 0.22 Midazolam, i.v. 
D6 
1.09 3.60 1.77 ± 0.21 (Zhang et al., 2009) 
Diltiazem 120mg, bid, 6d, p.o. 0.16 0.22 Midazolam 
D6 
2.01 9.30 4.11 ± 0.46 (Zhang et al., 2009) 
Saquinavir 1200mg, tid, 5d, p.o. 0.59 0.02 Midazolam, i.v. 
D3, 2h after 2nd 
1.14 4.37 2.49 (Palkama et al., 1999) 
Saquinavir 1200mg, tid, 5d, p.o. 0.59 0.02 Midazolam 
D3, 2h after 2nd 
2.25 11.48 5.14 (Palkama et al., 1999) 
Saquinavir 1200mg, tid, 7d, p.o. 1.15 0.02 Sildenafil 
D7 
3.75 10.24 3.10 (Muirhead et al., 2000) 
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* Inhibitor dose regimen: 400 mg, qd, 10d, p.o. represents the inhibitor dosed at 400 mg, once a day for 10 consecutive days;  ¶ The source of [I] is 
listed in the supplement data in details; דּ Victim drug: midazolam D12, 1h after 2nd  represents at the 12th day, midazolam was orally given 1h after 
Itraconazole 200 mg, qd, 4d,  p.o. 0.28 0.002 Midazolam 
D4, 1h after 
5.28 10.12 10.79 ± 0.12 (Olkkola et al., 1994) 
Itraconazole 200 mg, qd, 6d, p.o. 0.48 0.002 Midazolam 
D6, 2h after 
7.21 12.94 6.60 (Olkkola et al., 1996) 
Itraconazole 200 mg, qd, 6d, p.o. 0.11 0.002 Midazolam 
D1, 2h after 
3.28 6.07 3.4 (Olkkola et al., 1996) 
Itraconazole 200 mg, qd, 4d, p.o. 0.11 0.002 Midazolam 
D4 
3.27 6.07 6.75 (Backman et al., 1998) 
Itraconazole 100 mg, qd, 4d, p.o. 0.19 0.002 Midazolam 
D4, 2h after 
4.27 8.25 5.74 ± 0.15 (Ahonen et al., 1995) 
Conivaptan 40 mg, sd, p.o. 1.57 0.01 Midazolam 3.91 16.55 3.00 (NDA(021697) 
Conivaptan 40 mg, sd, p.o. 1.57 0.01 Midazolam, i.v. 1.91 6.42 2.00 (NDA 021697) 
Ritonavir 500mg,bid,7d, p.o. 14.09 0.02 Sildenafil 
D7 
12.27 12.46 11 (Muirhead et al., 2000) 
Ritonavir D1: 200mg, tid; D2; 
300mg, tid; D3: 
300mg, qd, p.o. 
11.09 0.02 Fentanyl, i.v. 
D2, 2h after 2nd 
1.36 1.36 2.7 (Olkkola et al., 1999) 
Ritonavir 200mg, bid, 2d, p.o. 1.66 0.02 Triazolam 
D2, 1h after 1st 
9.60 11.12 20.60 ± 1.09 (Greenblatt et al., 2000b) 
Ritonavir D1: 200mg, qd; D2; 
200mg, bid; D3: 
200mg, qd, p.o. 
2.21 0.02 Alprazolam 
D2, 1h after 1st 
4.99 5.57 2.47 ± 0.06 (Greenblatt et al., 2000a) 
Ritonavir 200mg, qd, 2d, p.o. 3.24 0.02 Trazodone 
D2, 1h after 1st 
2.02 2.05 2.34 ± 0.17 (Greenblatt et al., 2003) 
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the second dose of the inhibitor; # Single incubation time: utilizing the single IC50 value ( 20 min inhibitor incubation alone, the value listed in the 
first column in Table 1) with a model based on the reversible inhibition mechanism (Eq. 5) ; $ Mechanistic method: utilizing the inhibition 
parameters estimated from models A-C (values listed in Table 2) with the corresponding model for a given mechanism of inhibition (Eq. 5, 7 and 
8);  ¥ clinically observed DDIs calculated by AUC in the presence and absence of inhibitor; i.v: intravenous 
This article has not been copyedited and form
atted. The final version m
ay differ from
 this version.
D
M
D
 Fast Forw
ard. Published on January 6, 2011 as D
O
I: 10.1124/dm
d.110.036400
 at ASPET Journals on January 4, 2017 dmd.aspetjournals.org Downloaded from 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on January 6, 2011 as DOI: 10.1124/dmd.110.036400
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
Drug Metabolism and Disposition                                                                                                                                            DMD#36400 
Prediction of CYP3A Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma 
 
Jialin Mao, Michael A. Mohutsky, John P. Harrelson, Steven A. Wrighton and Stephen D. Hall 
JM, MAM, SAW and SDH: Department of Drug Disposition, Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN; JPH: School of 
Pharmacy, Pacific University, Hillsboro, OR 
 
 
Supplemental Table 1. The sources of the inhibitor concentration for each clinical DDI study 
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Inhibitor Inhibitor Dose 
Regimen* 
[I] 
(µM) 
Source of [I] 
 
Reference
Ketoconazole 400 mg, qd, 4d, p.o. 2.82 concentration at the time midazolam was given (Olkkola et al., 1994)
Ketoconazole 400 mg, qd, 10d, p.o. 2.82 concentration at the time midazolam was given (Chung et al., 2006)
Ketoconazole 200 mg, bid, 2d, p.o. 3.46 Cave calculated from the AUC0-8  (Tsunoda et al., 1999)
Ketoconazole 200 mg, bid, 2d, p.o 3.46 Cave calculated from the AUC0-8 (Tsunoda et al., 1999)
Ketoconazole 200 mg, bid, 2d, p.o. 4.76 Fahmi et al, 2009 (Eap et al., 2004)
Ketoconazole 200 mg, qd, 12d, p.o. 1.88 Fahmi et al, 2009 (Lam et al., 2003)
Ketoconazole 200 mg, sd, p.o. 1.87 Fahmi et al, 2009 (McCrea et al., 1999)
Fluconazole 400 mg, sd, p.o. 21.55 30 min after the uptake of midazolam (Olkkola et al., 1996)
Fluconazole D1: 400mg; D2-D5: 
200 mg, qd, p.o. 
29.99 30 min after the uptake of midazolam (Olkkola et al., 1996)
Fluconazole 100 mg, sd, p.o. 5.6 Einolf, 2007 (Kharasch et al., 2005)
Aprepitant 125mg, sd, p.o. 1.72 Cave calculated from the geometric mean AUC0-24 (Majumdar et al., 2003)
Aprepitant D1: 125mg; D2-5: 
80mg, qd, p.o. 
2.22 Cave calculated from the geometric mean AUC0-24 (Majumdar et al., 2003)
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Aprepitant 40mg, sd, p.o. 0.41 Cave calculated from the geometric mean AUC0-24 (Majumdar et al., 2003)
Aprepitant D1: 40mg; D2-5: 
25mg, qd, p.o. 
0.3 Cave calculated from the geometric mean AUC0-24 (Majumdar et al., 2003)
Aprepitant 125 mg, sd. p.o. 3.11 3h after midazolam geometric mean concentration (Majumdar et al., 2007)
Voriconazole D1: 400mg; D2: 
200mg, bid, p.o. 
1.64 Cave calculated from the AUC0-24 (Saari et al., 2006)
Voriconazole D1: 400mg; D2: 
200mg, bid, p.o. 
1.46 Cave calculated from the AUC0-24 (Saari et al., 2006)
Nefazodone D1-D4: 100mg titration 
to 200mg, bid; D5-
D12: 200mg, bid, p.o.
1.73 the trough concentration (Lam et al., 2003)
Troleandomycin 500 mg, bid, p.o. 1.76 Fahmi et al, 2009 (Phimmasone and Kharasch, 
2001) 
Troleandomycin 500 mg, bid, p.o. 1.76 Fahmi et al, 2009 (Kharasch et al., 2004)
Troleandomycin 500 mg, bid, p.o. 1.76 Fahmi et al, 2009 (Kharasch et al., 2004)
Erythromycin 200 mg, qid,7d,  p.o. 0.44 Fahmi et al, 2008 (Okudaira et al., 2007)
Erythromycin 200 mg, qid, 4d, p.o. 0.44 Fahmi et al, 2008 (Okudaira et al., 2007)
Erythromycin 200 mg, qid, 2d, p.o. 0.44 Fahmi et al, 2008 (Okudaira et al., 2007)
Erythromycin 500 mg, tid, 5d, p.o. 0.95 Fahmi et al, 2008 (Zimmermann et al., 1996)
Erythromycin 500 mg, tid, 6d, p.o. 4.22 concentration at 2-hour after the intake of 
erythromycin 
(Olkkola et al., 1993)
Erythromycin 500 mg, tid, 6d, p.o. 1.64 concentration at 2-hour after the intake of 
erythromycin 
(Olkkola et al. 1993)
Clarithromycin 500 mg, bid, 7d, p.o. 0.90 average steady state serum concentration (Gorski et al., 1998)
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Clarithromycin 500 mg, bid, 7d, p.o. 3.20 average steady state serum concentration (Quinney et al., 2008b)
Clarithromycin 250 mg, bid, 5d, p.o. 2.4 Fahmi et al, 2008 (Yeates et al., 1996)
Clarithromycin 500mg, bid, 7d, p.o. 0.90 average steady state serum concentration (Gorski et al., 1998)
Clarithromycin 500mg, bid, 7d, p.o. 3.20 average steady state serum concentration (Quinney et al., 2008b)
Clarithromycin 500mg, bid, 7d, p.o. 0.90 young volunteers, so concentration was used from 
Gorski et al, 1998 
(Gurley et al., 2008)
Clarithromycin 500mg, bid, 7d, p.o. 0.90 young volunteers, so concentration was used from 
Gorski et al, 1998 
(Gurley et al., 2006)
Diltiazem D1: 60mg, bid; D2: 
60mg, tid, p.o. 
0.38 mean concentration (Backman et al., 1994)
Diltiazem 120mg, bid, 6d, p.o. 0.16 unpublished clinical data from Hall et al, similar to the 
values observed from Lefebvre at al, 1993 
(Zhang et al., 2009)
Diltiazem 120mg, bid, 6d, p.o. 0.16 unpublished clinical data from Hall et al, similar to the 
values observed from Lefebvre at al, 1993 
(Zhang et al., 2009)
Saquinavir 1200mg, tid, 5d, p.o. 0.59 Cave calculated from the AUC0-8 (Palkama et al., 1999)
Saquinavir 1200mg, tid, 5d, p.o. 0.59 Cave calculated from the AUC0-8 (Palkama et al., 1999)
Saquinavir 1200mg, tid, 7d, p.o. 1.15 Cave calculated from the AUC0-8 (Muirhead et al., 2000)
Itraconazole 200 mg, qd, 4d,  p.o. 0.28 concentration at the time of midazolam was given (Olkkola et al., 1994)
Itraconazole 200 mg, qd, 6d, p.o. 0.48 concentration at 30-min after the intake of midazolam (Olkkola et al., 1996)
Itraconazole 200 mg, qd, 6d, p.o. 0.11 concentration at 30-min after the intake of midazolam (Olkkola et al., 1996)
Itraconazole 200 mg, qd, 4d, p.o. 0.11 same dose as Olkkola et al., 1996 (Backman et al., 1998)
Itraconazole 100 mg, qd, 4d, p.o. 0.19 concentration at the time of midazolam was given (Ahonen et al., 1995)
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Conivaptan 40 mg, sd, p.o. 1.57 mean Cmax at the end of the boarding dose 40mg (NDA(021697)
Conivaptan 40 mg, sd, p.o. 1.57 mean Cmax at the end of the boarding dose 40mg (NDA 021697)
Ritonavir 500mg,bid,7d, p.o. 14.09 Cave calculated from the AUC0-12 (Muirhead et al., 2000)
Ritonavir D1: 200mg, tid; D2; 
300mg, tid; D3: 300mg, 
qd, p.o. 
11.09 Cave calculated from the AUC0-8 (Olkkola et al., 1999)
Ritonavir 200mg, bid, 2d, p.o. 1.66 Cave calculated from the AUC0-8 (Greenblatt et al., 2000b)
Ritonavir D1: 200mg, qd; D2; 
200mg, bid; D3: 
200mg, qd, p.o.
2.21 Cave calculated from the AUC0-8 (Greenblatt et al., 2000a)
Ritonavir 200mg, qd, 2d, p.o. 3.24 calculated from the AUC0-8 (Greenblatt et al., 2003)
 
